A Novel Method for Determination of Thromboembolic Stroke Origin
ConditionThromboembolic Stroke
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorAtlantic Health System
About this trial
Rupture of vulnerable carotid, vertebral, and intracranial arterial plaques results in thromboembolic stroke. Identification of these culprit lesions is an important component of post-stroke care. This study seeks to test the feasibility of NaF PET-CT to detect these plaques and alter patient care. Prior studies have shown a high degree of correlation between NaF PET+ lesions and high-risk plaque features on high resolution MRI, including mirocalcification, necrosis, and ulceration.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial design
Design model
Single group
Treatments tested in this trial
NaF PET-CT
DrugFollowing a non-cardiogenic thromboembolic stroke, patients will undergo NaF PET-CT imaging to identify the culprit plaque and any other vulnerable plaques at high risk for rupture
Treatment groups
20 Participants
are divided into 1 treatment groupGroup A: Intervention - NaF PETExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Culprit lesion
Can NaF PET-CT within 14 days of a non-cardiogenic thromboembolic stroke identify the likely culprit plaque as a source of the stroke
Time frame
Within 14 days of the strokeSecondary outcomes
1
Recurrent stroke
Can NaF PET-CT within 14 days of a non-cardiogenic thromboembolic stroke predict the location of a future non-cardiogenic thromboembolic stroke
Time frame
Within 1 year of imaging2
Management change
Can NaF PET-CT within 14 days of a non-cardiogenic thromboembolic stroke alter patient management
Time frame
Within 1 year of imagingSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: